NECTIN4 and urothelial carcinoma: However, in the EV‐301 trial, the presence of Nectin‐4 expression was not set as an inclusion criterion, based on the assumption that nearly all advanced urothelial carcinoma exhibits high Nectin‐4 expression [1, 2, 4].